Genetics of hepatobiliary carcinogenesis

Seminars in Liver Disease

Volumn 31, Issue 2, 2011, Pages 173-187

  Nault, Jean Charles ^a,b   Zucman Rossi, Jessica ^a,b,c,d  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

Author keywords

catenin; genetic alterations; Hepatocellular carcinoma; P53; target therapy

Indexed keywords

AFLATOXIN B1; APC PROTEIN; BEVACIZUMAB; BRIVANIB; CATENIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; GLUTAMATE AMMONIA LIGASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; JANUS KINASE; K RAS PROTEIN; PROTEIN P53; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN; T CELL FACTOR PROTEIN; TRASTUZUMAB; UNINDEXED DRUG; UVOMORULIN; WNT PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CHROMOSOMAL INSTABILITY; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; ENZYME PHOSPHORYLATION; GENE DELETION; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS C; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 79955631558     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1276646     Document Type: Article

References (162)

1. El-Serag H B., Rudolph K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 7 2557-2576 (Pubitemid 46890874)
2. Tanabe K K., Lemoine A, Finkelstein D M. et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008 299 1 53-60
3. Zhang H, Zhai Y, Hu Z et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010 42 9 755-758
4. Malhi H, Gores G J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006 45 6 856-867 (Pubitemid 44646688)
5. Benhamouche S, Decaens T, Perret C, Colnot S. Wnt/beta-catenin pathway and liver metabolic zonation: a new player for an old concept. Med Sci (Paris) 2006 22 11 904-906
6. Micsenyi A, Tan X, Sneddon T, Luo J H., Michalopoulos G K., Monga S P. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004 126 4 1134-1146 (Pubitemid 38451184)
7. Cadoret A, Ovejero C, Terris B et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002 21 54 8293-8301 (Pubitemid 35477869)
8. Thompson M D., Monga S P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007 45 5 1298-1305 (Pubitemid 46775794)
9. Monga S P., Monga H K., Tan X, Mulé K, Pediaditakis P, Michalopoulos G K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003 124 1 202-216 (Pubitemid 36055352)
10. Monga S P., Pediaditakis P, Mule K, Stolz D B., Michalopoulos G K. Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001 33 5 1098-1109 (Pubitemid 32378208)
11. Rebouissou S, Couchy G, Libbrecht L et al. The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol 2008 49 1 61-71
12. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998 95 15 8847-8851 (Pubitemid 28350577)
13. Audard V, Grimber G, Elie C et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 2007 212 3 345-352 (Pubitemid 47017988)
14. Hsu H C., Jeng Y M., Mao T L., Chu J S., Lai P L., Peng S Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000 157 3 763-770
15. Mao T L., Chu J S., Jeng Y M., Lai P L., Hsu H C. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001 193 1 95-101
16. Legoix P, Bluteau O, Bayer J et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999 18 27 4044-4046 (Pubitemid 29361344)
17. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 2010 30 1 75-86
18. Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001 120 7 1763-1773 (Pubitemid 32523494)
19. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006 25 27 3778-3786 (Pubitemid 43980473)
20. Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010 42 Suppl 3 S235-S241
21. Miyoshi Y, Iwao K, Nagasawa Y et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998 58 12 2524-2527 (Pubitemid 28275419)
22. Terris B, Pineau P, Bregeaud L et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999 18 47 6583-6588
23. Yamashita T, Budhu A, Forgues M, Wang X W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007 67 22 10831-10839 (Pubitemid 350145912)
24. Merle P, Kim M, Herrmann M et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 2005 43 5 854-862 (Pubitemid 41414512)
25. Wong C M., Fan S T., Ng I O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001 92 1 136-145 (Pubitemid 32623050)
26. Cieply B, Zeng G, Proverbs-Singh T, Geller D A., Monga S P. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009 49 3 821-831
27. Peng S Y., Chen W J., Lai P L., Jeng Y M., Sheu J C., Hsu H C. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004 112 1 44-50 (Pubitemid 39249490)
28. Zulehner G, Mikula M, Schneller D et al. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 2010 176 1 472-481
29. Satoh S, Daigo Y, Furukawa Y et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000 24 3 245-250 (Pubitemid 30132191)
30. Zucman-Rossi J, Benhamouche S, Godard C et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007 26 5 774-780 (Pubitemid 46204256)
31. Ishizaki Y, Ikeda S, Fujimori M et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 2004 24 5 1077-1083
32. Taniguchi K, Roberts L R., Aderca I N. et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002 21 31 4863-4871 (Pubitemid 34879463)
33. Boyault S, Rickman D S., de Reyni?s A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007 45 1 42-52 (Pubitemid 46144363)
34. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001 7 3 594-599 (Pubitemid 32707984)
35. Kemp Z, Thirlwell C, Sieber O, Silver A, Tomlinson I. An update on the genetics of colorectal cancer. Hum Mol Genet 2004 13 Spec No 2 R177-R185 (Pubitemid 39359901)
36. Edamoto Y, Hara A, Biernat W et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003 106 3 334-341 (Pubitemid 36870393)
37. Zucman-Rossi J, Jeannot E, Nhieu J T. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006 43 3 515-524
38. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008 48 1 163-170 (Pubitemid 350199576)
39. Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007 51 6 855-856 (Pubitemid 350179403)
40. Rebouissou S, Amessou M, Couchy G et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009 457 7226 200-204
41. Puisieux A, Ponchel F, Ozturk M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 1993 8 2 487-490 (Pubitemid 23073765)
42. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991 350 6317 429-431 (Pubitemid 21912246)
43. Hsu I C., Metcalf R A., Sun T, Welsh J A., Wang N J., Harris C C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991 350 6317 427-428 (Pubitemid 21912245)
44. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991 338 8779 1356-1359
45. Hussain S P., Schwank J, Staib F, Wang X W., Harris C C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007 26 15 2166-2176 (Pubitemid 46536641)
46. Madden C R., Finegold M J., Slagle B L. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol 2002 76 22 11770-11774 (Pubitemid 35238005)
47. Wang B, Huang G, Wang D et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010 53 3 508-518
48. Karachristos A, Liloglou T, Field J K., Deligiorgi E, Kouskouni E, Spandidos D A. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol Cell Biol Res Commun 1999 2 3 155-161 (Pubitemid 129533212)
49. Zhang X, Xu H J., Murakami Y et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994 54 15 4177-4182 (Pubitemid 24258127)
50. Biden K, Young J, Buttenshaw R et al. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997 25 3 593-597 (Pubitemid 27106439)
51. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999 116 2 394-400 (Pubitemid 29055363)
52. Liew C T., Li H M., Lo K W. et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999 18 3 789-795 (Pubitemid 29080337)
53. Anzola M, Cuevas N, L?pez-Mart?nez M, Saiz A, Burgos J J., Mart?nez de Pancorboa M. P14ARF gene alterations in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004 16 1 19-26 (Pubitemid 39043698)
54. Peng C Y., Chen T C., Hung S P. et al. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res 2002 22 2B 1265-1271
55. Grivennikov S I., Greten F R., Karin M. Immunity, inflammation, and cancer. Cell 2010 140 6 883-899
56. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008 13 1 7-9 (Pubitemid 350309747)
57. Bromberg J F., Wrzeszczynska M H., Devgan G et al. Stat3 as an oncogene. Cell 1999 98 3 295-303 (Pubitemid 29380565)
58. Nault J C., Zucman-Rossi J. Building a bridge between obesity, inflammation and liver carcinogenesis. J Hepatol 2010 53 4 777-779
59. Grivennikov S, Karin E, Terzic J et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009 15 2 103-113
60. Yoshikawa H, Matsubara K, Qian G S. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001 28 1 29-35 (Pubitemid 32405812)
61. Okochi O, Hibi K, Sakai M et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 2003 9 14 5295-5298 (Pubitemid 37413582)
62. Calvisi D F., Ladu S, Gorden A et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006 130 4 1117-1128
63. Niwa Y, Kanda H, Shikauchi Y et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005 24 42 6406-6417 (Pubitemid 41486474)
64. Wong C I., Yap H L., Lim S G., Guo J Y., Goh B C., Lee S C. Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma. Hepatol Res 2008 38 8 838-841
65. Bekaii-Saab T, Williams N, Plass C, Calero M V., Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 2006 6 278
66. Su M C., Lien H C., Jeng Y M. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 2005 224 1 117-121
67. Xian Z H., Zhang S H., Cong W M., Wu W Q., Wu M C. Overexpression/ amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 2005 58 5 500-503
68. Collier J D., Guo K, Mathew J et al. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol 1992 14 2-3 377-380
69. Nussbaum T, Samarin J, Ehemann V et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008 48 1 146-156 (Pubitemid 351975539)
70. Tovar V, Alsinet C, Villanueva A et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 52 4 550-559
71. Oka Y, Waterland R A., Killian J K. et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 2002 35 5 1153-1163 (Pubitemid 34454012)
72. De Souza A T., Hankins G R., Washington M K., Orton T C., Jirtle R L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995 11 4 447-449
73. Kaposi-Novak P, Lee J S., Gomez-Quiroz L, Coulouarn C, Factor V M., Thorgeirsson S S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006 116 6 1582-1595
74. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 1997 25 4 862-866 (Pubitemid 27157127)
75. Park W S., Dong S M., Kim S Y. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999 59 2 307-310 (Pubitemid 29048858)
76. Ma P C., Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005 65 4 1479-1488 (Pubitemid 40270177)
77. Jun H T., Sun J, Rex K et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007 13 22 Pt 1 6735-6742 (Pubitemid 350206811)
78. Yang D H., Huang W, Cui J et al. The relationship between point mutation and abnormal expression of c-fms oncogene in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004 3 1 86-89 (Pubitemid 38256132)
79. Ridge S A., Worwood M, Oscier D, Jacobs A, Padua R A. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A 1990 87 4 1377-1380
80. Whittaker S, Marais R, Zhu A X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010 29 36 4989-5005
81. Leon M, Kew M C. Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res 1995 15 3 859-861
82. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989 80 3 196-199 (Pubitemid 20027206)
83. Challen C, Guo K, Collier J D., Cavanagh D, Bassendine M F. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992 14 2-3 342-346
84. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001 84 7 982-989 (Pubitemid 32385844)
85. Weihrauch M, Benick M, Lehner G et al. High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health 2001 74 6 405-410 (Pubitemid 32780719)
86. De Vivo I, Marion M J., Smith S J., Carney W P., Brandt-Rauf P W. Mutant c-Ki-ras p21 protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control 1994 5 3 273-278 (Pubitemid 24186018)
87. Tannapfel A, Sommerer F, Benicke M et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003 52 5 706-712 (Pubitemid 36528874)
88. Yeo W, Wong N, Wong W L., Lai P B., Zhong S, Johnson P J. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005 25 2 266-272
89. Zhang Y J., Ahsan H, Chen Y et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002 35 2 85-92
90. Villanueva A, Chiang D Y., Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 135 6 1972-1983, 1983, e1-e11
91. Chiang D Y., Villanueva A, Hoshida Y et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 68 16 6779-6788
92. Wang L, Wang W L., Zhang Y, Guo S P., Zhang J, Li Q L. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007 37 5 389-396 (Pubitemid 46605424)
93. Yao Y J., Ping X L., Zhang H et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999 18 20 3181-3185 (Pubitemid 29261240)
94. Lee J W., Soung Y H., Kim S Y. et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005 24 8 1477-1480 (Pubitemid 40343128)
95. Tanaka Y, Kanai F, Tada M et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006 25 20 2950-2952 (Pubitemid 43739246)
96. Monaco A P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009 87 2 157-163
97. Nakau M, Miyoshi H, Seldin M F., Imamura M, Oshima M, Taketo M M. Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res 2002 62 16 4549-4553
98. Kim C J., Cho Y G., Park J Y. et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer 2004 40 1 136-141 (Pubitemid 37542325)
99. Yakicier M C., Irmak M B., Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999 18 34 4879-4883 (Pubitemid 29423571)
100. Kawate S, Takenoshita S, Ohwada S et al. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999 14 1 127-131
101. Ching Y P., Wong C M., Chan S F. et al. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003 278 12 10824-10830
102. Ng I O., Liang Z D., Cao L, Lee T K. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000 60 23 6581-6584
103. Wong C M., Lee J M., Ching Y P., Jin D Y., Ng I O. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003 63 22 7646-7651 (Pubitemid 37466690)
104. Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002 32 2 312-315
105. Khan S A., Thomas H C., Toledano M B., Cox I J., Taylor-Robinson S D. p53 Mutations in human cholangiocarcinoma: a review. Liver Int 2005 25 4 704-716 (Pubitemid 41038651)
106. Tannapfel A, Benicke M, Katalinic A et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000 47 5 721-727
107. Ahrendt S A., Eisenberger C F., Yip L et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999 84 1 88-93 (Pubitemid 29391606)
108. Tannapfel A, Sommerer F, Benicke M et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002 197 5 624-631
109. Lee S, Kim W H., Jung H Y., Yang M H., Kang G H. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002 161 3 1015-1022 (Pubitemid 34988389)
110. Taniai M, Grambihler A, Higuchi H et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004 64 10 3517-3524 (Pubitemid 38657926)
111. Tozawa T, Tamura G, Honda T et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 2004 95 9 736-740 (Pubitemid 39335093)
112. Taniai M, Higuchi H, Burgart L J., Gores G J. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002 123 4 1090-1098
113. Weismller T J., Wedemeyer J, Kubicka S, Strassburg C P., Manns M P. The challenges in primary sclerosing cholangitisaetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008 48 Suppl 1 S38-S57
114. Isomoto H, Mott J L., Kobayashi S et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007 132 1 384-396 (Pubitemid 46108750)
115. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006 66 21 10517-10524 (Pubitemid 44799774)
116. Park J, Tadlock L, Gores G J., Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999 30 5 1128-1133 (Pubitemid 29510848)
117. Isomoto H, Kobayashi S, Werneburg N W. et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005 42 6 1329-1338 (Pubitemid 43260035)
118. Kobayashi S, Werneburg N W., Bronk S F., Kaufmann S H., Gores G J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005 128 7 2054-2065 (Pubitemid 40824713)
119. Hodge D R., Peng B, Cherry J C. et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005 65 11 4673-4682 (Pubitemid 40740803)
120. Isa T, Tomita S, Nakachi A et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002 49 45 604-608 (Pubitemid 34615308)
121. Ahrendt S A., Rashid A, Chow J T., Eisenberger C F., Pitt H A., Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000 7 4 426-431
122. Ohashi K, Nakajima Y, Kanehiro H et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995 109 5 1612-1617
123. Rijken A M., van Gulik T M., Polak M M., Sturm P D., Gouma D J., Offerhaus G J. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998 68 3 187-192 (Pubitemid 28359619)
124. Kubicka S, K?hnel F, Flemming P et al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut 2001 48 3 403-408 (Pubitemid 32269571)
125. Goldenberg D, Rosenbaum E, Argani P et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004 17 11 1386-1391 (Pubitemid 39472994)
126. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 1992 69 5 1115-1118
127. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993 8 4 312-318 (Pubitemid 24033243)
128. Sugimachi K, Taguchi K, Aishima S et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001 14 9 900-905 (Pubitemid 32889249)
129. Tokumoto N, Ikeda S, Ishizaki Y et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 2005 27 4 973-980
130. Gwak G Y., Yoon J H., Shin C M. et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 2005 131 10 649-652 (Pubitemid 41502207)
131. Leone F, Cavalloni G, Pignochino Y et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 2006 12 6 1680-1685
132. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005 206 3 356-365 (Pubitemid 40903200)
133. Yoshikawa D, Ojima H, Iwasaki M et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008 98 2 418-425 (Pubitemid 351161240)
134. Shibata T, Kokubu A, Gotoh M et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008 135 4 1358-1368, 1368, e1-e4
135. Hahn S A., Bartsch D, Schroers A et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998 58 6 1124-1126 (Pubitemid 28183196)
136. Riener M O., Bawohl M, Clavien P A., Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008 47 5 363-367 (Pubitemid 351451790)
137. Endo K, Ashida K, Miyake N, Terada T. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol 2001 193 3 310-317 (Pubitemid 32229861)
138. Marongiu F, Doratiotto S, Montisci S, Pani P, Laconi E. Liver repopulation and carcinogenesis: two sides of the same coin? Am J Pathol 2008 172 4 857-864 (Pubitemid 351519983)
139. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006 45 1 1-4 (Pubitemid 43850628)
140. Roskams T A., Theise N D., Balabaud C et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004 39 6 1739-1745 (Pubitemid 38702678)
141. Clouston A D., Powell E E., Walsh M J., Richardson M M., Demetris A J., Jonsson J R. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005 41 4 809-818 (Pubitemid 40462943)
142. Richardson M M., Jonsson J R., Powell E E. et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007 133 1 80-90 (Pubitemid 47031146)
143. Ziol M, Nault J C., Aout M et al. Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis. Gastroenterology 2010 139 1 335-343, e2
144. Mishra L, Banker T, Murray J et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009 49 1 318-329
145. Lee J S., Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006 12 4 410-416
146. Hoshida Y, Nijman S M., Kobayashi M et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 69 18 7385-7392
147. Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J Gastroenterol 2006 12 39 6261-6265 (Pubitemid 44712404)
148. Haratake J, Hashimoto H. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver 1995 15 1 9-15
149. Komuta M, Spee B, Vander Borght S et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008 47 5 1544-1556 (Pubitemid 351702738)
150. Llovet J M., Ricci S, Mazzaferro V et al, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 4 378-390
151. Cheng A L., Kang Y K., Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 10 1 25-34
152. Abou-Alfa G K., Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 24 26 4293-4300 (Pubitemid 46630787)
153. Flaherty K T., Puzanov I, Kim K B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 363 9 809-819
154. Ferté C, André F, Soria J C. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010 7 7 367-380
155. Thomas M B. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 2007 61 1 44-51 (Pubitemid 44880150)
156. Eckel F, Schmid R M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007 96 6 896-902 (Pubitemid 46452283)
157. Valle J, Wasan H, Palmer D H. et al, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 362 14 1273-1281
158. Zhu A X., Meyerhardt J A., Blaszkowsky L S. et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010 11 1 48-54
159. Lubner S J., Mahoney M R., Kolesar J L. et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010 28 21 3491-3497
160. Bengala C, Bertolini F, Malavasi N et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010 102 1 68-72
161. Yoshikawa D, Ojima H, Kokubu A et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009 100 8 1257-1266
162. Malka D, Trarbach T, Fartoux L et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol 2009 27 15s 4520